Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
CADILAHC On Other Exchanges
Symbol
Exchange
CADILAHC is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

cadila healthcare ltd (CADILAHC) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CADILA HEALTHCARE LTD (CADILAHC)

Related News

No related news articles were found.

cadila healthcare ltd (CADILAHC) Related Businessweek News

No Related Businessweek News Found

cadila healthcare ltd (CADILAHC) Details

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, veterinary, and human formulations. The company offers branded formulations in the therapeutic areas of neurological, neutraceutical, pain management, gastro intestinal, respiratory, anti-infective, biological, cardiovascular, female healthcare, dermatology, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company researches and develops a pipeline of 24 biologics comprising 20 biosimilars and 4 novel biological products; and new drugs in cardio-metabolic, inflammation, pain, and oncology therapeutic areas. Further, it provides animal healthcare products. Additionally, the company develops vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, HPV, and combination vaccines. The company was founded in 1952 and is headquartered in Ahmedabad, India.

Founded in 1952

cadila healthcare ltd (CADILAHC) Top Compensated Officers

Chairman, Managing Director, Chairman of Shar...
Total Annual Compensation: 148.3M
Chief Financial Officer and Member of Risk Ma...
Total Annual Compensation: 25.6M
Deputy Managing Director, Director, Member of...
Total Annual Compensation: 100.0M
Compliance Officer and Company Secretary
Total Annual Compensation: 2.5M
Compensation as of Fiscal Year 2015.

cadila healthcare ltd (CADILAHC) Key Developments

Cadila Healthcare Limited Approves Dividend for the Year 2014-2015

Cadila Healthcare Limited announced that at the AGM held on August 12, 2015, it has approved a dividend of INR 12 (@ 240%), aggregating to INR 2,456,982,240 on 204,748,520 equity shares of INR 5 each, be and is hereby declared and that the dividend shall be made payable to those members of the company whose names appear in the register of members of the company on August 12, 2015 in respect of members holding shares in physical from and as per list of beneficiaries provided by depositories as on book closure date with respect to the members holding shares in electronic form.

Cadila Healthcare Limited Reports Unaudited Consolidated and Company Earnings Results for the First Quarter Ended June 30, 2015

Cadila Healthcare Limited reported unaudited consolidated and company earnings results for the first quarter ended June 30, 2015. For the quarter, on consolidated basis, the company reported total income from operations of INR 25,006.5 million compared to INR 20,501.2 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 5,278.3 million compared to INR 3,084.1 million a year ago. Profit from ordinary activities before tax was INR 5,332.0 million compared to INR 2,995.6 million a year ago. Net profit for the period was INR 3,609.1 million or INR 17.26 per basic and diluted share before and after extraordinary items compared to INR 2,471.2 million or INR 11.73 per basic and diluted share before and after extraordinary items a year ago. Earnings before interest, depreciation and tax were up by 60% year on year to INR 6.02 billion. Net debt has come down by around about INR 4,000 million. For the quarter, on company basis, the company reported total income from operations of INR 19,150.2 million compared to INR 11,127.9 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 6,669.9 million compared to INR 2,109.0 million a year ago. Profit from ordinary activities before tax was INR 6,744.5 million compared to INR 2,189.9 million a year ago. Net profit for the period was INR 5,557.5 million or INR 27.14 per basic and diluted share before and after extraordinary items compared to INR 1,972.9 million or INR 9.64 per basic and diluted share before and after extraordinary items a year ago.

Cadila Healthcare Limited, Q1 2016 Earnings Call, Aug 12, 2015

Cadila Healthcare Limited, Q1 2016 Earnings Call, Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDH:IN 1,865.40 INR +23.75

CADILAHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 655.65 INR +7.35
Glenmark Pharmaceuticals Ltd 1,062 INR -17.45
Piramal Enterprises Ltd 885.80 INR -8.00
Torrent Pharmaceuticals Ltd 1,650 INR +24.50
Wockhardt Ltd 1,325 INR +29.00
View Industry Companies
 

Industry Analysis

CADILAHC

Industry Average

Valuation CADILAHC Industry Range
Price/Earnings 28.6x
Price/Sales 4.0x
Price/Book 8.5x
Price/Cash Flow 23.2x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.